Amgen (AMGN) Tops Q2 EPS by 38c, Offers FY Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $3.97, $0.38 better than the analyst estimate of $3.59. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.68 billion.

GUIDANCE:

Amgen sees FY2019 EPS of $13.75-$14.30, versus the consensus of $13.97. Amgen sees FY2019 revenue of $22.4-22.9 billion, versus the consensus of $22.59 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
• GSX Techedu Inc. (GOTU) Misses Q2 EPS by 11c; offers guidance
• Amkor Tech jumps 9% as BofA initiates Buy with $70 target on AI surge